Evidence map›Paper›PMID 39920846›Full record

ArticleStem cell research & therapy2025

MSCs with upregulated lipid metabolism block hematopoietic stem cell differentiation via exosomal CTP-1A in MDS.

Chunlai Yin, Xue Yan, Jinyi Ren, Cheng Zhang, Jiaqing Liu, Zilong Wang, Jing Liu, Weiping Li, Xia Li

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chunlai Yin *Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, China.
Xue Yan *Department of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, China.
Jinyi RenDepartment of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, China.
Cheng ZhangDepartment of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, China.
Jiaqing LiuDepartment of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, China.
Zilong WangDepartment of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, China.
Jing LiuCollege of Pharmacy, Dalian Medical University, Dalian, 116044, Liaoning, China.
Weiping LiDepartment of Hematology, the Second Hospital of Dalian Medical University, Dalian, 116027, Liaoning, China. liweiping0910@sina.com.
Xia LiDepartment of Immunology, College of Basic Medical Science, Dalian Medical University, Dalian, 116044, Liaoning, China. lixia416@163.com.

Funding

Basic Research Projects of Liaoning Provincial Department of Education JYTQN2023152Basic Scientific Research Project (Key Project) of the Education Department of Liaoning Province LJ212410161034Dalian Medical University Interdisciplinary Research Cooperation Project Team Funding JCHZ2023010Doctoral Start-up Foundation of Liaoning Province 2021-BS-205National Natural Science Foundation of China 82071834National Natural Science Foundation of China 82271839
6 · The paper itself

Abstract

backgroundMyelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells (HSCs), characterized by ineffective hematopoiesis and a high risk of progression to acute myeloid leukemia. Elucidating the mechanism underlying the dysfunction of MDS-HSCs is crucial for exploring the pathogenesis of the syndrome. While previous studies have implicated mesenchymal stem cells (MSCs), a principal component of the bone marrow (BM) microenvironment, in the inhibition of normal hematopoiesis, the precise molecular mechanisms have not been fully elucidated. In this study, we investigated the effects of MSCs from MDS patients on hematopoietic functions of HSCs from a metabolic perspective.

methodsMSCs were isolated from BM of MDS patients. The proliferation, apoptosis, differentiation and support for hematopoiesis of these cells were analyzed using CCK-8 assay, FC and induction medium and CFU (colony forming units) assay, respectively. Expression levels of metabolic molecules were used as indicators to screen MSCs with different metabolic pathways and were detected by RT-PCR and Western blotting. Exosome derived from MSCs were isolated from the culture supernatant and confirmed by Transmission Electron Microscope, Dynamic Light Scattering and Western blotting. The effects of these exosomes on HSCs were analyzed using the same methods as those used to assess MSCs function.

resultsOur findings demonstrated that MDS-MSCs exhibited significant functional impairments, including reduced proliferation, impaired differentiation, diminished support for hematopoiesis, and increased apoptosis. Notably, we observed an upregulation of lipid metabolism in these MSCs, which appears to contribute to their dysfunction. Intriguingly, the aberrant lipid metabolic profile can be effectively reversed by the administration of etomoxir (ETO), an inhibitor of carnitine palmitoyltransferase 1A (CPT-1A). Furthermore, MSCs with enhanced lipid metabolism could transmit this dysfunction to HSCs through the secretion of exosomes that are enriched in CPT-1A.

conclusionsWe suggest that the MDS BM microenvironment disrupts MSCs metabolism by increasing the expression of CPT-1A, which impairs the ability to support normal HSCs. Interestingly, the suppressive effect is mediated by exosomes rich in CPT-1A, which derived from MSCs. These findings provide novel insights into MDS MSCs-metabolism-Exosome axis in ineffective hematopoiesis and offer new strategies for the treatment of MDS.

Indexed as

Cell DifferentiationExosomesHematopoietic Stem CellsLipid MetabolismMesenchymal Stem CellsMyelodysplastic SyndromesApoptosisCell ProliferationCells, CulturedFemaleHematopoiesisHumansMaleMiddle AgedUp-RegulationCPT-1AExosomeHematopoietic stem cellMesenchymal stem cellMyelodysplastic syndrome

Identifiers

PMID39920846
PMCPMC11806692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.